8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Apr 23, 2026·SEC
BridgeBio Oncology Therapeutics Inc.(BBOT)Earnings, Financials & Key Ratios
BBOT•NASDAQ
$8.29
Price updated Jul 7, 2026
AboutBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.Show more
- Revenue$0
- EBITDA-$145M-80.0%
- Net Income-$134M-80.5%
- EPS (Diluted)-4.30-1034.8%
- ROE-44.7%+43.2%
BBOT Price & Volume
BridgeBio Oncology Therapeutics Inc. (BBOT) stock price & volume — 10-year historical chart
Loading chart...
BBOT Growth Metrics
BridgeBio Oncology Therapeutics Inc. (BBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-90.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-289.52%
Return on Capital
10 Years-87548.75%
5 Years-87548.75%
3 Years-116727.24%
Last Year-48%
BBOT Recent Earnings
BridgeBio Oncology Therapeutics Inc. (BBOT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (40%)
Q3 2026Latest
Jun 4, 2026Metric
Actual
Est
EPS
$0.53-2.8%
$0.51
Rev
—
—
Q2 2026
May 12, 2026Metric
Actual
Est
EPS
$0.49+4.5%
$0.51
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.48+24.2%
$0.63
Rev
—
—
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.56-33.3%
$0.42
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 4, 2026 | $0.53vs $0.51-2.8% | — |
| Q2 2026 | May 12, 2026 | $0.49vs $0.51+4.5% | — |
| Q2 2026 | Mar 5, 2026 | $0.48vs $0.63+24.2% | — |
| Q2 2026 | Mar 4, 2026 | $0.56vs $0.42-33.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BridgeBio Oncology Therapeutics Inc. (BBOT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.29 | $664.09M | -1.93 | — | — | -44.7% | — | |
| $77.91 | $15.26B | -20.56 | 126.26% | -125.17% | — | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — |
Compare BBOT vs Peers
BridgeBio Oncology Therapeutics Inc. (BBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBOT SEC Filings & Documents
BridgeBio Oncology Therapeutics Inc. (BBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BBOT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BBOT Frequently Asked Questions
BridgeBio Oncology Therapeutics Inc. (BBOT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BBOT profitable?
BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $154.1M for fiscal year 2025.
Dividend & Returns
What is BBOT's return on equity?
BridgeBio Oncology Therapeutics Inc. (BBOT) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
What is BridgeBio Oncology Therapeutics Inc.'s free cash flow?
BridgeBio Oncology Therapeutics Inc. (BBOT) had negative free cash flow of $172.9M in fiscal year 2025, likely due to heavy capital investments.